SCHEMBL7658353

SCHEMBL7658353

Cc1cc(C(=O)Cl)c(Br)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.39
LMNA P02545 3/20 0.39
MAPK1 P28482 1/20 0.39
MAPT P10636 5/20 0.36
GAA P10253 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TSHR P16473 1/20 0.34
DAO P14920 2/20 0.33
HSD17B10 Q99714 2/20 0.33
PSMD14 O00487 1/20 0.33
MMP2 P08253 1/20 0.33
ALOX15 P16050 1/20 0.33
NPSR1 Q6W5P4 3/20 0.33
HTT P42858 2/20 0.33
HPGD P15428 1/20 0.33
GSK3B P49841 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PKM P14618 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2825614 0.81 ALDH1A1 (0.53) ALDH1A1LMNAMAPK1MAPTGAA
SCHEMBL19436829 0.79 ALDH1A1 (0.40) ALDH1A1LMNAMAPK1MAPTGAA
SCHEMBL11845297 0.78 ALDH1A1 (0.41) ALDH1A1LMNAMAPK1MAPTGAA
SCHEMBL28713332 0.78 GSK3B (0.35) ALDH1A1TSHRDAOALOX15GSK3B
SCHEMBL10861141 0.76 HSP90AB1 (0.39) ALDH1A1LMNAMAPK1MAPTGAA
SCHEMBL17398205 0.76 SMN1; SMN2 (0.47) ALDH1A1LMNAMAPK1MAPTGAA
SCHEMBL16445841 0.73 GAA (0.49) ALDH1A1LMNAMAPK1MAPTGAA
SCHEMBL456389 0.71 GSK3B (0.39) ALDH1A1MAPTDAOGSK3B
SCHEMBL11848129 0.68 ALDH1A1 (0.35) ALDH1A1LMNAMAPK1MAPTGAA
SCHEMBL8285092 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
CN-1268949-A Fused thiophene compounds and medical use thereof YOSHITOMI PHARMACEUTICAL (JP) 2000-10-04 CN disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT ALDH1A1 366/4885LMNA 4763/4885MAPK1 1616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.